Fact Sheet PDF

Download PDF

Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With an outstanding capacity for innovative drug discovery, advanced biotechnology research and development, a whole-industry-chain approach with large-scale production technology, and drug combinations with great market potential, Junshi Biosciences has endless potential in onco-immunotherapy as well as the treatment of autoimmune diseases, metabolic diseases, neurological diseases and infectious diseases.

Share Graph

SHARE DATA 14/04/2025	JUNSHI BIO A	JUNSHI BIO H
Currency	CNY	HKD
Previous Close	30.50	15.18
Volume	9,856,468	3,655,040
Change (%)	4.45	7.81
Market Cap (mil)	23,375.02	3,328.91
Number of Shares (mil)	766.39	219.30

FINANCIAL HIGHLIGHTS (RMB'000)	2021	2022	2023
Consolidated Income Statement
Revenue	4,024,841	1,453,493	1,502,550
Gross profit	2,766,654	927,211	835,260
Research and development expenses	(2,068,739)	(2,384,373)	(1,937,470)
Loss before tax	(592,648)	(2,675,202)	(2,489,887)
Loss for the year	(728,181)	(2,582,095)	(2,533,882)
Consolidated Balance Sheet
Total assets	11,050,720	12,576,286	11,362,464
Total liabilities	2,718,538	2,782,036	4,022,256
Total equity	8,332,182	9,794,250	7,340,208
Consolidated Cash Flow Statement
Net cash used in operating activities	(641,901)	(1,775,325)	-
Net cash used in investing activities	(1,880,952)	(467,619)	-
Net cash from financing activities	2,665,686	4,643,009	-
Cash and cash equivalents at end of the year, represented by bank balances and cash	3,504,605	5,996,936	-
Key indicators
Loss per share (RMB)	(0.80)	(2.60)	(2.32)

*The above financial data are prepared in accordance with IFRS